Seoul Commercial Real Estate Hits Bottom: Recovery Slower Than Apartments

주메뉴 바로가기
본문 바로가기

2025.06.30 (월)

기상청 제공

닫기

English

홈
English

Seoul Commercial Real Estate Hits Bottom: Recovery Slower Than Apartments

이종화 기자 macgufin@empas.com
등록 2024.10.25 07:00:00

However, the recovery of commercial real estate is still slower than the residential market, where apartment prices are hitting new records. Industry experts suggest that while the market has not reached. [RSQUARE]

[NewsSpace=Jack Moon] Seoul's commercial real estate market is showing signs of recovery after a period of sluggishness due to high interest rates.

In July 2023, the number of commercial building transactions in Seoul increased by 23% compared to the previous month, totaling 187 deals worth 2 trillion won. Although the figure represents a 28.9% decrease from June, it marks a 81.2% increase in YoY.

Investment returns are also on the rise, with office spaces in Seoul showing a 1.99% return in Q2, up 0.15 percentage points from the previous quarter. The Gangnam district, in particular, saw significant increases in both office and retail space returns.

However, the recovery of commercial real estate is still slower than the residential market, where apartment prices are hitting new records.

Industry experts suggest that while the market has not reached the level of the 2020-2021 boom, it is maintaining a positive trend, with expectations of continued stability amid anticipation of potential interest rate cuts.

이종화 기자의 전체기사 보기

이 시각 추천뉴스

Fair Trade Commission Gives Hyosung Group a Free Pass for Its ‘Abusive’ Technology Requirements… Will It Be Over if They Just Pay 3 Billion Won?

[News Space=Reporter seungwon lee] The Fair Trade Commission has initiated a 'consent resolution' procedure to provide an opportunity for voluntary correction without determining whether Hyosung Group, which is under investigation for unfairly requesting technical data from subcontractors, has violated the law. Hyosung proposed a 3 billion won win-win plan, and the Fair Trade Commission accepted it, opening the way for a quick conclusion to the case. This decision is raising controversy over whether the consent system is being reduced to an 'indulgence.' Hyosung, unreasonably demanding technic

Beauty regulators in Asia gather at ‘Korea Kolmar’… Visit ‘K-Beauty R&D Heart’ to check Korea’s competitiveness

[News Space=Reporter seungwon lee] High-ranking government officials in charge of cosmetics regulations in Asian countries visited Kolmar Korea. With K-beauty recently gaining popularity in the global market, they wanted to directly check out Kolmar Korea’s global research and development system and hear opinions on exports. Korea Kolmar announced on the 2nd that cosmetics regulatory authorities from major Asian countries visited Korea Kolmar’s General Technology Center on the 30th of last month. The visit was attended by about 20 people, including regulatory authorities from 7 Asian countries

Human division 'Samsung Bio' catches three rabbits... Bio global super gap, strengthening of Lee Jae-yong's control, asset value reevaluation 'a stroke of genius'

[News Space=Reporter seungwon lee] Samsung BioLogics is drastically reorganizing its business structure through a spin-off. On the 22nd, Samsung BioLogics announced through a public disclosure that it will split the company into the surviving corporation, ‘Samsung BioLogics’, which will be in charge of the contract development and manufacturing organization (CDMO) business, and the newly established corporation, ‘Samsung Epi Holdings’, which will act as an investment and holding company for biosimilar and new drug development. This split is a strategic decision to strengthen the expertise and

Lee Hae-jin, who went to Taiwan, met Jensen Huang, and the ‘AI alliance’ began in earnest… Naver and Nvidia ‘discuss’ cooperation on Sovereign AI

[News Space=Reporter seungwon lee] Naver Chairman Lee Hae-jin met with NVIDIA CEO Jensen Huang in Taiwan and signaled a new phase in the global AI leadership competition. This meeting was held during Asia's largest IT exhibition, 'Computex 2025', and NVIDIA's cloud partner event, 'NPC Summit', and the discussion on 'Sovereign AI' cooperation, which combines Naver's AI strategy and NVIDIA's infrastructure, emerged as a key agenda. Naver executives mobilize to attack Southeast Asia AI market in earnest Chairman Lee Hae-jin visited Taiwan with key executives, including Naver CEO Choi Soo-yeon and

Osstem Pharma participates in China Beauty Expo… Viewsen fever ‘hot’, global strategy ‘accelerates’

[News Space=Reporter seungwon lee] Osstem Pharma (CEO Moon Byeong-jeom), a subsidiary of Osstem Implant, announced that it received enthusiastic interest and response by introducing an exhibition booth for its premium oral care brand 'Viewsen' at the 'China Beauty Expo 2025 (CBE)' held at the Shanghai International Expo Center from May 12 to 14. CBE is the largest beauty trade show in Asia. This year, in its 29th year, over 3,500 companies from 80 countries around the world opened booths and attracted over 500,000 visitors. Osstem Pharma set up a brand promotion booth centered around the Views

Novartis, Profitability Regresses Despite Sales Increase… Net Income Approaching Dividends, Patent Infringement Lawsuits, Cash Assets 0 Won 'Risk'

[News Space=Reporter seungwon lee] Despite the increase in sales in 2024, Novartis Korea (CEO Yoo Byung-jae) saw its profitability decline as both operating profit and net profit decreased. The operating profit ratio also fell to 3.7%. In addition, short-term borrowings increased and cash assets remain at 0 won, making liquidity management weak. The scale of purchases and debts with special related parties (head office, etc.) is large, and the financial structure has improved somewhat due to inventory asset reduction and restructuring (dramatic reduction in retirement benefits), but the group

Celltrion Signs Contract with Large US PBM for 'Stekima' Listing… Full-scale Expansion of Reimbursement Coverage

[News Space=Reporter seungwon lee] Celltrion has successfully expanded its coverage by signing a formulary listing contract for its autoimmune disease treatment drug 'Steqeyma' (ingredient name: ustekinumab) with one of the top five prescription drug benefit managers (PBM) in the United States. As Celltrion secures the private insurance area under the jurisdiction of the PBM through this contract, Stekima is scheduled to receive a refund starting July 1. This contract is the second achievement that Celltrion has made with a large US PBM for the listing of Stekima in the formulary. Prior to thi

Daewon Pharmaceutical Risk (Part 4): From ‘Domestic New Drug Myth’ to ‘Bad Company’ Stigma… 4 Consecutive Patent Losses, Quality Risk, and the ‘Bare Face’ of Family Management

[News Space=Reporter seungwon lee] Daewon Pharmaceutical, once the pride of domestic new drugs, has lost four consecutive patent lawsuits for ‘Pelubi’ from the first trial to the Supreme Court, exposing its management incompetence and structural risks at once. In recent years, Daewon Pharmaceutical has been criticized as a typical ‘bad company’ due to repeated investigations by the Ministry of Food and Drug Safety and the National Tax Service, as well as repeated defeats in court. ◆ Four consecutive patent lawsuit losses… The fall of the Pelubi myth Daewon Pharmaceutical’s domestic new drug ‘P

“Risk to subcontractor, profit to general contractor” Hyundai-Kia industrial accidents reveal their true colors… ‘Conveyor belt of death’ is ongoing

[News Space=Reporter seungwon lee] The symbol of Korean manufacturing: Hyundai and Kia Motors factories. The workers there are called “new production workers” with hundreds of millions of won in annual salaries, but behind the splendid facade, there are industrial accidents, occupational diseases, and the tears of subcontracted workers. Even more shocking is the tyranny of Hyundai and Kia Motors, which evades all responsibility with their powerful power and capital. Over the past five years, more than 2,061 people were injured, and 28 people lost their lives… “Passing responsibility to subcont